Kerstin Haase

Kerstin Haase

Auto-generated profile, based on publicly available information

Kerstin Haase

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2022 in Nature
Verified
Journal Article
Open access
PDF file
CSChristopher D. Steele
Christopher D. Steele
AAAmmal Abbasi
Ammal Abbasi
SIS. M. Ashiqul Islam
S. M. Ashiqul Islam
ABAmy L. Bowes
Amy L. Bowes
AKAzhar Khandekar
Azhar Khandekar
NPNischalan Pillay
Nischalan Pillay
Gains and losses of DNA are prevalent in cancer and emerge as a consequence of inter-related processes of replication stress, mitotic errors, spindle multipolarity and breakage–fusion–bridge cycles, among others, which may lead to chromosomal instability and aneuploidy1,2. These copy number alterations contribute to cancer initiation, progression and therapeutic resistance3–5. Here we present a conceptual framework to examine the patterns of copy number alterations in human cancer that is widely applicable to diverse data types, including whole-genome sequencing, whole-exome sequencing, reduced representation bisulfite sequencing, single-cell DNA sequencing and SNP6 microarray data. Deploying this framework to 9,873 cancers representing 33 human cancer types from The Cancer Genome Atlas6 revealed a set of 21 copy number signatures that explain the copy number patterns of 97% of samples. Seventeen copy number signatures were attributed to biological phenomena of whole-genome doubling, aneuploidy, loss of heterozygosity, homologous recombination deficiency, chromothripsis and haploidization. The aetiologies of four copy number signatures remain unexplained. Some cancer types harbour amplicon signatures associated with extrachromosomal DNA, disease-specific survival and proto-oncogene gains such as MDM2. In contrast to base-scale mutational signatures, no copy number signature was associated with many known exogenous cancer risk factors. Our results synthesize the global landscape of copy number alterations in human cancer by revealing a diversity of mutational processes that give rise to these alterations.

2 September 2020 in Nature
Verified
Journal Article
Closed access
PDF file
TWThomas B. K. Watkins
Thomas B. K. Watkins
ELEmilia L. Lim
Emilia L. Lim
MPMarina Petkovic
Marina Petkovic
SESergi Elizalde
Sergi Elizalde
ABAnd Nicolai J. Birkbak
And Nicolai J. Birkbak
CSCharles Swanton
Charles Swanton

15 June 2022 in Nature
Verified
Journal Article
Closed access
PDF file
RDRuben M. Drews
Ruben M. Drews
BHBarbara Hernando
Barbara Hernando
MTMaxime Tarabichi
Maxime Tarabichi
KHKerstin Haase
Kerstin Haase
TLTom Lesluyes
Tom Lesluyes
FMFlorian Markowetz
Florian Markowetz

5 March 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TCTRACERx Consortium
TRACERx Consortium
SLSaioa López
Saioa López
ELEmilia L. Lim
Emilia L. Lim
SHStuart Horswell
Stuart Horswell
KHKerstin Haase
Kerstin Haase
NMNicholas McGranahan
Nicholas McGranahan

23 June 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
SBSam Behjati
Sam Behjati
PTPatrick S. Tarpey
Patrick S. Tarpey
KHKerstin Haase
Kerstin Haase
HYHongtao Ye
Hongtao Ye
MYMatthew D. Young
Matthew D. Young
PCPeter J. Campbell
Peter J. Campbell
Osteosarcoma is a primary malignancy of bone that affects children and adults. Here, we present the largest sequencing study of osteosarcoma to date, comprising 112 childhood and adult tumours encompassing all major histological subtypes. A key finding of our study is the identification of mutations in insulin-like growth factor (IGF) signalling genes in 8/112 (7%) of cases. We validate this observation using fluorescence in situ hybridization (FISH) in an additional 87 osteosarcomas, with IGF1 receptor (IGF1R) amplification observed in 14% of tumours. These findings may inform patient selection in future trials of IGF1R inhibitors in osteosarcoma. Analysing patterns of mutation, we identify distinct rearrangement profiles including a process characterized by chromothripsis and amplification. This process operates recurrently at discrete genomic regions and generates driver mutations. It may represent an age-independent mutational mechanism that contributes to the development of osteosarcoma in children and adults alike.

16 November 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
KHKonstantin Helmsauer
Konstantin Helmsauer
M(Maria Stefanova (Valieva)
Maria Stefanova (Valieva)
SASalaheddine Ali
Salaheddine Ali
RGRocío Chamorro González
Rocío Chamorro González
RSRobert Schöpflin
Robert Schöpflin
RKRichard P. Koche
Richard P. Koche
MYCN amplification drives one in six cases of neuroblastoma. The supernumerary gene copies are commonly found on highly rearranged, extrachromosomal circular DNA (ecDNA). The exact amplicon structure has not been described thus far and the functional relevance of its rearrangements is unknown. Here, we analyze the MYCN amplicon structure using short-read and Nanopore sequencing and its chromatin landscape using ChIP-seq, ATAC-seq and Hi-C. This reveals two distinct classes of amplicons which explain the regulatory requirements for MYCN overexpression. The first class always co-amplifies a proximal enhancer driven by the noradrenergic core regulatory circuit (CRC). The second class of MYCN amplicons is characterized by high structural complexity, lacks key local enhancers, and instead contains distal chromosomal fragments harboring CRC-driven enhancers. Thus, ectopic enhancer hijacking can compensate for the loss of local gene regulatory elements and explains a large component of the structural diversity observed in MYCN amplification.